Literature DB >> 27357906

MicroRNA-214 exerts a Cardio-protective effect by inhibition of fibrosis.

Hua Dong1, Shimin Dong2, Lisi Zhang1, Xueping Gao2, Guangwei Lv2, Wei Chen1, Suxia Shao3.   

Abstract

The miRNAs play important roles in regulating myocardial fibrosis. The purpose of this study was to determine the potential roles of microRNA-214 (miR-214) in cardiac fibrosis in vitro and in vivo. In vitro experiment, Ang II-induced cardiac fibroblasts (CFBs) are transfected with pre-miR-214, anti-miR-214 and their oligo controls. Gene expression was checked by Quantitative realtime-PCR (qRT-PCR) and western blotting. In the present experiment, compared with controls, expressions of collagen type I (COL I), collagen type III (COL III), transforming growth factor (TGF)-β1, and tissue inhibitors of metalloproteinase (TIMP)-1 were all increased, but matrix metalloproteinase (MMP)-1 was reduced in CFB by Ang II treatment at both mRNA and protein levels, and these alterations were found reversed by miR-214 transfection. In vivo, an anterior transmural acute myocardial infarction (AMI) was created by occlusion of the left anterior descending coronary artery after Ad-pre-miR-214, Ad-anti-miR-214 or Ad-GFP was delivered separately. Four weeks after AMI, protein contents of COL I, COL III and TGF-β1 in tissue from border area were found increased after AMI, but impaired by overexpression of miR-214. While the expression of MMP-1 was increased by miR-214 stimulation but decreased by miR-214 inhibition. These results suggested that miR-214 exerts cardio-protective effects by inhibition of fibrosis and the inhibitory effect involves TGF-β1 suppression and MMP-1/TIMP-1 regulation. Anat Rec, 299:1348-1357, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  MMP-1/TIMP-1; TGF-β1; collagen; miR-214; myocardial fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27357906     DOI: 10.1002/ar.23396

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  7 in total

1.  Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy.

Authors:  Patrício Aguiar; Olga Azevedo; Rui Pinto; Jacira Marino; Carlos Cardoso; Nuno Sousa; Damião Cunha; Derralynn Hughes; José Luís Ducla Soares
Journal:  J Am Heart Assoc       Date:  2018-03-13       Impact factor: 5.501

Review 2.  Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis.

Authors:  Yongfeng Yang; Hong Huang; Yi Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

3.  Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts.

Authors:  Wen-Si Zhu; Chun-Mei Tang; Zhen Xiao; Jie-Ning Zhu; Qiu-Xiong Lin; Yong-Heng Fu; Zhi-Qin Hu; Zhuo Zhang; Min Yang; Xi-Long Zheng; Shu-Lin Wu; Zhi-Xin Shan
Journal:  Oncotarget       Date:  2016-11-29

4.  MicroRNA-495 inhibits the high glucose-induced inflammation, differentiation and extracellular matrix accumulation of cardiac fibroblasts through downregulation of NOD1.

Authors:  Xiaowei Wang; Haiying Jin; Shifeng Jiang; Yanlan Xu
Journal:  Cell Mol Biol Lett       Date:  2018-05-09       Impact factor: 5.787

5.  Loss of AZIN2 splice variant facilitates endogenous cardiac regeneration.

Authors:  Xinzhong Li; Xiang He; He Wang; Mengsha Li; Senlin Huang; Guojun Chen; Yuanwen Jing; Shifei Wang; Yanmei Chen; Wangjun Liao; Yulin Liao; Jianping Bin
Journal:  Cardiovasc Res       Date:  2018-10-01       Impact factor: 10.787

6.  Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension.

Authors:  Zuzana Kmecova; Jana Veteskova; Katarina Lelkova-Zirova; Lenka Bies Pivackova; Gabriel Doka; Eva Malikova; Ludovit Paulis; Peter Krenek; Jan Klimas
Journal:  J Cell Mol Med       Date:  2020-05-12       Impact factor: 5.310

Review 7.  MicroRNA-214 in Health and Disease.

Authors:  Meer M J Amin; Christopher J Trevelyan; Neil A Turner
Journal:  Cells       Date:  2021-11-23       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.